Fierce Biotech News & Reports
WEB4 days ago · Fierce Biotech covers the latest news, analysis and data in the world of biotech and pharma R&D. Read about the Fierce 50 of 2024, medtech innovations, biopharma collaborations and more.
MedTech | Fierce Biotech
WEB5 days ago · Fierce Biotech covers the latest developments and trends in the MedTech industry, including clinical trials, regulatory approvals, mergers and acquisitions, and innovations. Read about Abbott's ...
Grail delivers final study results showing its blood test's accuracy in ...
WEBJun 25, 2021 · The final results from a Grail study of its cancer-tracing blood test found it was accurate at detecting a range of different tumors at early stages—especially those more likely to be lethal and ha
A look at the R&D landscape in obesity, led by GLP-1s - Fierce …
WEBMar 19, 2024 · The obesity pipeline features 124 medicines, mostly GLP-1 agonists, in various stages of development. Novo and Lilly dominate the market, but face competition from smaller biotechs and Big Pharma.
PerkinElmer completes $2.45B split into two separate companies
WEBMar 14, 2023 · PerkinElmer has completed the $2.45 billion spinoff of its applied science, food and enterprise services businesses to New Mountain Capital. The remaining company, yet to be named, will focus on ...
BD upsizes San Diego presence with new 220K-square ... - Fierce …
WEBNov 22, 2021 · BD Biosciences, a segment of medtech giant BD, has leased a 220,000-square-foot space on the Torrey View campus in San Diego. The facility will serve as an expanded reagent innovation center for ...
Bristol Myers pays $800M upfront for antibody-drug conjugate
WEBDec 12, 2023 · Bristol Myers Squibb pays $800 million upfront for BL-B01D1, a bispecific antibody-drug conjugate (ADC) that targets EGFR and HER3 in NSCLC and other cancers. The deal is part of BMS' strategy to ...
New AI drug discovery powerhouse Xaira rises with $1B in funding
WEBApr 24, 2024 · Xaira is a San Francisco-based company that aims to rethink drug discovery with machine learning, data generation and therapeutic product development. It was co-founded by David Baker, Marc ...
BMS enters radiopharma race with $4.1B acquisition of RayzeBio
WEBDec 27, 2023 · Bristol Myers Squibb acquires RayzeBio, a biotech focused on actinium-based radiopharmaceuticals for cancer, just three months after its IPO. The deal follows BMS' acquisition of Karuna ...
Genentech to close cancer immunology research department
WEBAug 16, 2024 · Ira Mellman, a renowned cell biologist and leader of Genentech's cancer immunology research, will depart after 17 years with the company. The move comes amid broader R&D rethink and pipeline ...